NovaBridge to Showcase Pipeline at H.C. Wainwright BioConnect Conference
Event summary
- NovaBridge Biosciences to present at H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026.
- Fireside chat scheduled for 3:30 PM ET, webcast available for 90 days post-event.
- Company's pipeline includes givastomig (Claudin 18.2 X 4-1BB bispecific antibody) and VIS-101 (dual VEGF-A X ANG-2 inhibitor).
- Givastomig in Phase 2 study for gastric cancer; VIS-101 Phase 2b study expected to start in H2 2026.
The big picture
NovaBridge's participation in the H.C. Wainwright conference underscores its focus on investor engagement amid key clinical milestones. The company's dual pipeline strategy—targeting oncology with givastomig and ophthalmology with VIS-101—positions it in high-growth therapeutic areas. Success hinges on translating Phase 2 data into differentiated clinical outcomes.
What we're watching
- Pipeline Progress
- Whether givastomig's Phase 2 results will validate its first-in-class potential in gastric cancer.
- Execution Risk
- The pace at which VIS-101 advances through Phase 2b, given its competitive landscape in retinal diseases.
- Strategic Partnerships
- How NovaBridge leverages collaborations with ABL Bio and Visara to accelerate development timelines.
Related topics